Skip to main content
OpenTrials
Completed

NCT Number: NCT01474590

Efficacy & Safety Comparison of Epiduo With Doxycycline Versus Vehicle With Isotretinoin in the Treatment of Severe Acne

Non-inferiority, randomized, controlled, multi-center, investigator-blind, parallel-group comparison study in subjects with severe acne vulgaris on the face.

Completed

Looking for future studies?

Notify Me

Key information

Age range

12 year–35 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Galderma investigational site, Ajax, Canada

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female subject of any race, aged 12 to 35 years inclusive
  • Subject weighing between 50 and 110 kg
  • Subject with severe acne (IGA at least 4), which in the opinion of the investigator is appropriate for treatment with oral isotretinoin (severe nodular acne, severe inflammatory acne, recalcitrant acne; all unresponsive to conventional first line therapies)
  • Subject with at least 5 nodules on the face

Exclusion criteria

  • Subject with clinically abnormal results to blood testings performed at screening
  • Subject with acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne, etc.), pyoderma faciale, sinus tracks
  • Female subject who is pregnant, nursing or planning a pregnancy during the study
  • Subject with known history of hepatic and/or renal insufficiency, to be confirmed by blood testings
  • Subject with known metabolic or structural bone disease (for 12-17 years old population)
  • Subject with bowel disease and/or with hypervitaminosis A
  • Subject who presents with treated or untreated depression or has a history of depression including a family history of major depression
  • Subject with a wash-out period from baseline for topical treatment on the face less than : Corticosteroids, antibiotics, antibacterials, antiseptics, retinoids, other anti-inflammatory drugs or other acne treatments (2 weeks); Cosmetic procedures (1 week); Photodynamic therapy and laser therapy for acne (3 months)
  • Subject with a wash-out period from baseline for systemic treatment less than: Corticosteroids, antibiotics (4 weeks),Progesterone for contraception (3 months); Spironolactone(3 months); Other acne treatments (6 months);Cyproterone acetate(6 months)

Treatment and study plan

Epiduo/Tactuo

Drug

topical to the face, once daily in the evening

Vehicle gel

Other

topical to the face, once daily in the evening

doxycycline 200mg

Drug

oral, 2 capsules once daily in the morning with aglass of water and with food

isotretinoin

Drug

oral, 0.5mg/kg/day for a period of four weeks, adjusted to 1 mg/kg/day for the four following months.

Primary outcomes

  1. The Primary Outcome is Overall Success, a Composite Endpoint Including Efficacy and Safety Measurements

    Time frame: 20 weeks

    Overall success is reached when the 2 following criteria are fulfilled :

    • Overall efficacy: reduction of at least 75% of number of nodules at the end of treatment
    • Safe treatment: Absence of any listed safety issues

Sponsors and collaborators

Lead sponsor

Galderma R&D

Industry

Registry information

Official study title

Efficacy and Safety Comparison of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel Associated With 200 mg Doxycycline Capsules Versus Vehicle Gel Associated With Isotretinoin Capsules in the Treatment of Severe Acne

Acronym: POWER

Important dates

Study start
2011
Primary completion
2013
Study completion
2013
First posted
Nov 18, 2011
Registry last updated
Feb 18, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.